EXPLANATORY NOTE - SUPPLEMENTAL
On February 24, 2025, Petco Health and Wellness Company, Inc. filed this Current Report on Form 8-K/A with the Securities and Exchange Commission via the EDGAR system. This filing on Form 8-K/A was inadvertently filed via EDGAR indicating that it was a Form 8-K filing. This amendment is filed for the sole purpose of filing via EDGAR to properly reflect that this filing is a Form 8-K/A filing. This Form 8-K/A filing is otherwise identical in all respect to the Form 8-K filed on February 24, 2025, which should have been filed as a Form 8-K/A filing.
EXPLANATORY NOTE
This Current Report on Form 8-K/A amends Item 5.02 of the Current Report on Form 8-K filed on February 18, 2025 (the “Report”) by Petco Health and Wellness Company, Inc. (the “Company”) to add the information described herein.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 18, 2025, the Company filed the Report to disclose that (i) Sabrina Simmons succeeded Brian LaRose as the Company’s Chief Financial Officer (the “CFO Succession”), effective as of February 17, 2025 (the “Transition Date”), and (ii) as of the Transition Date, Mr. LaRose became a full-time non-officer employee of the Company, and is expected to remain employed for a transition period ending on April 30, 2025 (the “Separation Date”).
This Current Report on Form 8-K/A hereby amends the Report to disclose that on February 20, 2025, in connection with the CFO Succession, Mr. LaRose entered into a transition and separation agreement and general release of claims (the “Agreement”) with Petco Animal Supplies Stores, Inc., an indirect wholly owned subsidiary of the Company, pursuant to which Mr. LaRose agreed to provide transition services to the Company as an employee through the Separation Date. Further, in consideration for a general release of claims and certain other covenants, the Agreement also provides Mr. LaRose with the following separation payments and benefits: (i) a lump sum cash payment of $730,392, representing 12 months of Mr. LaRose’s base salary and 12 months of group health plan continuation premiums; (ii) a pro-rata portion of the actual annual incentive that Mr. LaRose would have earned for the 2025 fiscal year, pro-rated through the Transition Date; and (iii) a lump sum cash payment of $27,945, representing the retention bonus for the third installment period under his retention bonus agreement, pro-rated through the Transition Date. Mr. LaRose will also remain eligible to receive his annual incentive for the 2024 fiscal year based on actual performance.
The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the complete terms of the Agreement filed as Exhibit 10.1 hereto, which is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits